Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Retained Earnings (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Retained Earnings data on record, last reported at -$344.1 million in Q3 2025.

  • For Q3 2025, Retained Earnings fell 16.06% year-over-year to -$344.1 million; the TTM value through Sep 2025 reached -$344.1 million, down 16.06%, while the annual FY2024 figure was -$297.1 million, 21.6% down from the prior year.
  • Retained Earnings reached -$344.1 million in Q3 2025 per SNTI's latest filing, down from -$326.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $1000.0 in Q4 2022 and bottomed at -$344.1 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$176.5 million, with a median of -$201.4 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: surged 100.0% in 2022, then tumbled 24434500.0% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$115.1 million in 2021, then soared by 100.0% to $1000.0 in 2022, then crashed by 24434500.0% to -$244.3 million in 2023, then fell by 21.6% to -$297.1 million in 2024, then dropped by 15.81% to -$344.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$344.1 million in Q3 2025, -$326.0 million in Q2 2025, and -$311.2 million in Q1 2025.